Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Drospirenone-Ethinyl Estradiol vs Cyproterone Acetate-Ethinyl Estradiol on FAI in PCOS
NCT07911709Completed
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Open-label trial of drospirenone and ethinyl estradiol in polycystic ovary syndrome (PCOS) (2 arms). Primary endpoints: Total testosterone at 12 weeks, Sex hormone binding globulin at 12 weeks and 1 more. Started Jul 2023; status: completed.
02
Drugs
drospirenoneethinyl estradiol
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT07911709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911709.